Bladder cancer is one of the most prevalent cancers worldwide, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75% of bladder cancer cases. While the standard piecemeal transurethral resection of bladder tumor (SR) has been the conventional surgical procedure for NMIBC, oncological control remains subpar, prompting the development of alternative techniques such as en bloc transurethral resection of bladder tumor (ERBT). To examine the impact of ERBT on the prognosis of NMIBC, Professor Teoh, Yuen-Chun Jeremy and his team conducted a local phase 3 randomized controlled trial, EB-StaR, that compared the 1-year recurrence rate of NMIBC with ERBT to SR. In an interview with Omnihealth Practice, Prof. Teoh discussed the implications of the results and the future of ERBT implementation.

Prostate cancer (PCa) has the highest reported incidence rate among common male cancers in Hong Kong during the past two decades.¹ It is the fourth leading cause of cancer-related deaths among males in Hong Kong.